Mektovi and Itching - a phase IV clinical study of FDA data

Summary:

Itching is reported as a side effect among people who take Mektovi (binimetinib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Braftovi, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Itching when taking Mektovi. It is created by eHealthMe based on reports of 6,177 people who have side effects when taking Mektovi from the FDA, and is updated regularly.

What is Mektovi?

Mektovi has active ingredients of binimetinib. eHealthMe is studying from 6,179 Mektovi users. Check the latest studies of Mektovi.

What is Itching?

Itching is found to be associated with 3,213 drugs and 4,526 conditions by eHealthMe. Check the latest studies of Itching.

On May, 23, 2026

6,177 people reported to have side effects when taking Mektovi.
Among them, 119 people (1.93%) have Itching.

Among these 119 people:

* Approximation only. Some reports may have incomplete information.

Do you take Mektovi and have Itching?

- Check whether Itching is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mektovi:

Mektovi (6,179 reports)

Itching treatments and more:

Itching (398,818 reports)

How severe was Itching and when was it recovered:

Itching in Mektovi

Expand to all the drugs that have ingredients of binimetinib:

Itching and drugs with ingredients of binimetinib

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mektovi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Itching:

Itching (3,213 drugs)

Browse all the conditions that are associated with Itching:

Itching (4,526 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on binimetinib (the active ingredients of Mektovi) and Mektovi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.